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Abstract: Mental ill health is currently one of the leading causes of disease burden worldwide.
A growing body of data has emerged supporting the role of diet, especially polyphenols, which have
anxiolytic and antidepressant-like properties. The aim of the present study was to assess the effect of
a high polyphenol diet (HPD) compared to a low polyphenol diet (LPD) on aspects of psychological
well-being in the Polyphenol Intervention Trial (PPhIT). Ninety-nine mildly hypertensive participants
aged 40–65 years were enrolled in a four-week LPD washout period and then randomised to either an
LPD or an HPD for eight weeks. Both at baseline and the end of intervention, participants’ lifestyle
and psychological well-being were assessed. The participants in the HPD group reported a decrease
in depressive symptoms, as assessed by the Beck Depression Inventory-II, and an improvement in
physical component and mental health component scores as assessed with 36-Item Short Form Survey.
No differences in anxiety, stress, self-esteem or body image perception were observed. In summary,
the study findings suggest that the adoption of a polyphenol-rich diet could potentially lead to
beneficial effects including a reduction in depressive symptoms and improvements in general mental
health status and physical health in hypertensive participants.
Keywords: polyphenols; fruits; berries; vegetables; dark chocolate; psychological well-being;
depression; physical health; mental health
1. Introduction
Mental ill health, manifesting itself in a wide range of conditions such as depression, anxiety
and stress [1], represents one of the leading causes of burden of disease worldwide, also substantially
increasing the risk of cardiovascular disease, diabetes and cancer [2–4] and adversely affecting quality
of life (QoL), relationships and the ability to work [5]. Northern Ireland has the highest prevalence of
mental illness within the UK, and psychiatric morbidity is 25% higher than in the UK [6].
Thus, research is required in order to establish inexpensive and effective techniques to reduce the
incidence of mental health problems and to improve the psychological well-being of the population.
Alongside genetic and biological factors, researchers have increasingly begun to examine the role
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of lifestyle factors, including dietary intake, in the promotion of psychological well-being and the
prevention of mental illness [7,8]. Studies that have explored potential associations between nutrient
intake (namely carbohydrates, B vitamins and antioxidants such as vitamins C, E and polyphenols)
or foods rich in these nutrients (e.g., fruits, vegetables, legumes, coffee, chocolate) and psychological
well-being have produced conflicting results [9–12].
Polyphenols, in particular, have gained increasing attention from health researchers in recent
years due to their biological properties, as well as their abundance within the human diet [13].
A growing number of epidemiological studies support a role for polyphenols in the prevention
of chronic non-communicable diseases such as cardiovascular disease (CVD) [14], cancer [15] and
neurodegenerative diseases [14,16]. Furthermore, animal studies have demonstrated the ability of
polyphenols to improve cognitive performance and memory [17,18] and, more recently, these results
have been replicated in human studies [19,20]. Regarding mental health, a growing body of data from
animal and human studies has emerged supporting the role of a variety of dietary polyphenols in
affecting behaviour and mood through anxiolytic and antidepressant-like properties, mediated through
multiple molecular and cellular pathways [21]. Moreover, given that recent studies have demonstrated
the pathophysiological role of oxidative stress and inflammation in the onset and progression of
depression, polyphenols have been examined both in vitro and in vivo as a potential antidepressant
treatment, although randomised controlled trials are still scarce in the field [22,23]. The richest sources
of polyphenols in the human diet include fruits (e.g., berries, grapes, apples and plums), vegetables
(e.g., cabbage, eggplant, onions, peppers), plant-derived beverages including tea, coffee, red wine
and fruit juices (e.g., apple juice), seeds, nuts and chocolate (particularly dark chocolate) [24,25].
In terms of a food-based approach, several of the above-mentioned foods have been studied both in
observational and intervention studies for potential effects on outcomes related to mental well-being,
mood, psychological distress and life satisfaction [26], although, potentially due in part to the great
variation in study design, results are not consistent. Studying diet on a dietary pattern level will be
beneficial in allowing potential complicated or cumulative intercorrelations, interactions and synergies
to be revealed, given that different polyphenols may have different effects on outcomes of mental
health [27–29].
The aim of the present study was to assess the effect of a polyphenol-rich dietary pattern
(comprising fruits, including berries; vegetables and dark chocolate) in comparison to a control
diet (low fruits and vegetables, <2 portions/day, and no dark chocolate) on aspects of psychological
well-being and mental health status including mood, QoL, body image perception and self-esteem as
secondary outcomes measured within the Polyphenol Intervention Trial (PPhIT) [30].
2. Materials and Methods
2.1. Setting and Study Population
PPhIT was a randomised, controlled, parallel-group, single-blinded dietary intervention trial,
primarily designed to test whether increasing overall polyphenol dietary intake would affect
microvascular function and a range of other markers of CVD risk, such as systolic blood pressure and
lipid profile, in patients with hypertension. All participants underwent a full assessment at baseline
(week 0) (described below); then, they entered a washout period, during which they consumed a
low polyphenol diet, and afterwards were randomised to either a low polyphenol diet (LPD) or a
high polyphenol diet (HPD) group for 8 weeks (Figure 1). A full assessment was repeated for all the
participants at the end of the 8-week intervention (week 12), while at the end of the washout period
(week 4), participants also underwent a dietary intake assessment, anthropometric measurements and
blood and urine sample collection.
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Participants aged 40–65 years, with documented grade I (140–159/90–99 mmHg) or grade II
(160–179/100–109 mmHg) hypertension, were eligible. Participants with diabetes mellitus, acute
coronary syndrome or transie t ischaemic attack within three months, pregnancy or lactation, fasting
triglyceride concentration >4 mmol/L, alcohol consumption (>28 units/week for m n and >21 units/week
for wom n), oral anticoagulant therapy or antioxidant supplemen s, dietary restrictions that would
limit ability o comply with the study diets, body mass index >35 kg/m2 or with an impalpabl brachial
artery were excluded from the study. Recruitment for PPhIT began in Febru ry 2011 and was co pleted
by January 2013. All participants were informed about the aims and procedures of the stu y and gave
their ritten consent. The study had ethical approval fro the Office of Research Ethics Committee
Northern Ireland (ref 10/NIR03/39) and was registered at ClinicalTrials.gov (ref NCT01319786). Details
of the primary aim of the study, population, design, recruitment procedures and main findings have
been published elsewhere [30]. Below, we provide some additional details on selected aspects of the
evaluation that pertain to the analyses reported in this manuscript.
2.2. Dietary Intervention
The intervention commenced with a four-week “washout period” for all participants, during
which they were asked to consume two portions or less of fruits and vegetables (F&V) per day and to
exclude berries and ark chocolate (LPD). At the end of this period, subjects were ra domised to either
continue with the b ve LPD fo a further 8-week “intervention peri d” or to consume an HPD of six
portions of F&V (including one portion of berries per day) and 50 g of dark chocolate per day (Figure 1).
A portion of fruit and vegetables was quantitatively defined using household measures as outlined by
UK guidelines (https://www.nhs.uk/live-well/eat-well/5-a-day-portion-sizes/), i.e., 1 apple, 1 orange,
half a grapefruit or one glass (150 mL) fruit juice, 3 tablespoons of vegetables [31]. All participants in
the HPD had a self-selected weekly delivery of F&V and dark chocolate (Lindt® 70% cocoa) free of
charge to their homes from a local supermarket and were provided with written material regarding
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F&V portion sizes, recipes and sample diet plans. In addition, each participant, regardless of dietary
allocation, was also contacted by telephone at weekly intervals to provide support and encouragement
and to discuss potential barriers encountered in relation to achieving the dietary goals.
Dietary intake and compliance with the intervention were assessed through 4-day food diaries
completed on four occasions: on the four days leading up to the week 0 visit (baseline measurement),
on the four days leading up to the week 4 visit (washout period measurement), at week 8 (intervention
measurement) and on the four days leading up to the final week 12 visit (a second intervention period
measurement). Circulating blood and urine levels of a panel of nutritional biomarkers, with detailed
methodology given below, were also used to assess compliance. Self-reported F&V, berries and dark
chocolate consumed per day (as recorded in the food diaries) were extracted and entered into a
Microsoft Excel spreadsheet. The spreadsheet contained pre-determined formulae which transformed
the actual amounts of F&V and berries consumed into “portions” according to the “5-a-day” message.
2.3. Other Lifestyle Parameters
A “lifestyle and medical” questionnaire was used at week 0 to record participant demographic,
lifestyle and medical information. The questionnaire had 16 items in total and assessed several aspects
including vitamin and mineral supplement usage, smoking and alcohol habits, history of education,
current occupational status, current medication, history of steroid use and, for females, use of hormone
replacement therapy and details of menstrual cycle. Information regarding changes in medication use,
smoking and alcohol patterns, as well as infections/illnesses were also recorded throughout the study.
Participants’ physical activity levels were recorded at weeks 0, 4 and 12 to ensure that habitual
activity levels were not altered for the duration of the study. The Recent Physical Activity Questionnaire
(RPAQ), designed by the Medical Research Council (MRC Epidemiology Unit, Cambridge, UK),
was used to measure physical activity. The questionnaire assesses physical activity within the
preceding four weeks based on three primary areas: activity at home, activity at work (including travel
to and from work) and recreational activities. The RPAQ has been shown to be a valid instrument
for calculating total energy expenditure, physical activity energy expenditure and physical activity
in healthy adults [32]. In terms of analysis, physical activity as recorded in the questionnaire was
converted to total metabolic equivalent of task (MET) hours per day of sedentary, light, moderate and
vigorous activity.
2.4. Anthropometric, Clinical and Biochemical Assessments
Participants attended the Royal Victoria Hospital (Belfast, Northern Ireland, UK) for assessments
on three occasions throughout the study: baseline (week 0), washout period (week 4) and intervention
(week 12). Body weight of participants was measured to the nearest 100 g and height to the nearest
0.5 cm. Body mass index (BMI) was calculated as weight (kg) divided by height squared (m2).
Waist circumference (WC) and hip circumference (HC) were tape-measured to the nearest 0.1 cm.
Blood pressure (BP) was measured using an Omron M5-1 automatic BP monitor (Omron Healthcare,
Hoofddorp, The Netherlands). Three consecutive readings were recorded, and a mean BP was
calculated from the 2nd and 3rd readings. To measure the primary endpoint of PPhIT (microvascular
function), venous occlusion plethysmography was conducted on participants by determining forearm
blood flow during incremental intra-arterial infusions of acetylcholine and sodium nitroprusside,
as previously described [30]. Blood samples were also collected. Fasting serum lipid profiles
(total cholesterol, high density lipoprotein (HDL) and triglycerides) were assessed using standard
enzymatic colorimetric assays on an automated Cobas® 8000 Modular system biochemical analyser
(Roche Diagnostics Ltd., West Sussex, UK). Low-density lipoprotein (LDL) cholesterol was calculated
using a standard Friedewald formula [33]. Blood and urine markers of micronutrient status were
assessed at weeks 0 and 12 to objectively measure compliance to the intervention diet. Plasma
vitamin C was measured on a FLUOstar Optima plate reader (BMG Labtech, Ortenberg, Germany),
adapted from the method of Vuilleumier and Keck [34]. Serum concentrations of six carotenoids
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(α-carotene, β-carotene, β-cryptoxanthin, lutein, lycopene and zeaxanthin) were measured by reverse
phase high performance liquid chromatography (HPLC), as described by Craft [35]. Urine collected
from the volunteers between evening meal and midnight the evening before each study visit was
analysed, including an enzymatic hydrolysis step, to quantify total epicatechin content, using an
Agilent Technologies 1100 series HPLC (Agilent Technologies, Stockport, UK) directly linked to a Waters
Micromass Quattro Ultima Platinum API triple quadrupole mass spectrometer (Waters, Dublin, Ireland).
2.5. Psychological Well-Being, Self-Esteem and Body Image
Aspects of psychological well-being and mental health status were evaluated through several scales
and questionnaires that were completed at weeks 0 and 12. The decision to use these questionnaires
only twice was made for three reasons: (i) the study wished to investigate the effect of the intervention
diet in comparison to normal psychological well-being, rather than psychological well-being under the
controlled conditions of the washout period; (ii) to reduce participants’ burden at week 4 visits, which
were already long (2.5 h) in duration due to vascular function and dietary assessments; (iii) distributing
the surveys at three time points may have been disadvantageous in terms of allowing participants
to become familiar with their format, which may have influenced responses. All questionnaires are
commonly used for assessing various aspects of mental health and psychological well-being in the
general population.
The Positive and Negative Affect Schedule (PANAS) was used for evaluating subjective mood.
The questionnaire measures two distinctive dimensions: positive affect (PA) and negative affect
(NA) [36]. PA is associated with pleasurable engagement with the environment, including feelings of
enthusiasm and alertness as well as feeling active. NA refers to unpleasurable engagement with the
environment, comprising feelings of anger, contempt, disgust, guilt, fear and nervousness. Whilst
related, PA and NA represent two distinct and independent dimensions of mood. Participants were
asked to respond to 10 items representing PA and 10 items representing NA on a five-point scale. Higher
scores represent higher positive and negative affect, respectively. This was the only questionnaire
assessing psychological well-being that was also completed at week 4, in order to monitor psychological
well-being at the end of the washout period.
Depressive symptomology was assessed with the Beck Depression Inventory-II (BDI-II), a 21-item,
self-report questionnaire developed by Beck and colleagues [37]. Each item on the BDI-II has four
statements which relate to the severity of a particular depressive symptom, and respondents are asked
to choose the one statement which best describes how they have been feeling in the preceding two
weeks. Higher scores indicate higher levels of depression (scores 0–13 = minimal; 14–19 = mild;
20–28 = moderate; 29–63 = severe). The shorter version (21 items) of the Depression Anxiety Stress
Scale (DASS-21) was also completed to measure depression, anxiety and stress [38]. The DASS-21
questionnaire was introduced nine months into the recruitment of the participants. DASS-21 has seven
items per subscale and asks participants to rate the extent to which they experienced each emotional
state the preceding week using a four-point Likert scale (0 = Did not apply to me at all, 3 = Applied to
me very much or most of the time). Higher scores are indicative of higher levels of depression, anxiety
and stress.
The Rosenberg Self-Esteem Scale was used as a global measure of self-esteem [39,40].
The questionnaire consists of a ten-item Likert scale, completed using a four-point scale from strongly
agree to strongly disagree. Scores can range from 0 to 30, with higher scores indicating higher
self-esteem. Finally, body image satisfaction was assessed through the Multidimensional Body
Self-Relations Questionnaire—Appearance Scales (MSRQ-AS), a 34-item validated measure of body
image perception for use in general populations (www.body-images.com) [41]. This version contains
five subscales: appearance evaluation (satisfaction with ones looks), appearance orientation (levels of
investment in one’s appearance), overweight preoccupation (weight anxiety, vigilance, dieting etc),
self-classified weight (how one perceives and labels one’s weight) and body area satisfaction (satisfaction
with areas of body). The questionnaire contains a series of statements and asks participants to indicate
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the extent to which each statement applies to them personally, with higher scores generally indicating
greater body image satisfaction.
2.6. Mental and Physical Health
Mental and physical health were assessed with the RAND Medical Outcomes Study 36-item
Short Form Health Survey (SF-36) [42,43]. A total of 36 questions are included in the RAND SF-36
survey and eight key areas are explored in the SF-36 including physical functioning, role limitations
due to physical problems, pain, general health, energy/fatigue, social functioning, role limitations
due to emotional problems and emotional well-being. The raw data were recoded using the RAND
SF-36 scoring instructions available online. Additionally, the eight areas were combined to obtain
the scoring for physical and mental health components. As the eight different components consist
of different numbers of questions, the normal scores were transformed to T-scores, as described by
Hays et al. 1993 [44] and Hays et al. 1995 [45]. Physical functioning, role limitations due to physical
problems, pain and general health were combined to obtain the physical health component and role
limitations due to emotional problems, energy/fatigue, emotional well-being and social functioning
were combined to obtain the mental health component.
2.7. Statistical Analyses
The sample size calculation was based on the PPhIT primary outcome, namely microvascular
function. According to this, detection of a 33% difference between groups in microvascular function,
measured by forearm blood flow responses to an endothelium-dependent vasodilator, with 90% power,
using a 2-tailed test at the 5% significance level, would require 50 participants per group. The current
analysis reports secondary outcomes, for which power calculations were not performed.
Results are expressed as mean ± standard deviation for normally distributed continuous variables
and as medians and interquartile ranges for continuous skewed variables. Categorical variables are
presented as absolute (n) and relative frequencies (%). The normality of variables was checked through
the Shapiro–Wilk test and graphically through histograms. Concentration measures of micronutrients
were logarithmically transformed and were summarised as geometric median and interquartile range.
The principal analysis for each outcome variable was a between-group comparison of change using
independent sample t tests or Mann–Whitney U test for continuous parametric and non-parametric
variables, respectively, and chi-squared test for categorical variables. Within-group comparisons were
performed using paired sample t tests or Wilcoxon signed-rank test for parametric and non-parametric
continuous variables, respectively. Statistical significance was set at p ≤ 0.05. All statistical methods
were conducted using PASW Statistics 18 for Windows (SPSS Inc., Chicago, IL, USA).
3. Results
3.1. General Results
Ninety-nine participants completed the PPhIT study, including 53 (53.5%) males. Participants had
a mean age of 54.9 ± 6.9 years, with ages ranging from 40 to 65 years. The majority (52%) of the sample
were obese (BMI ≥ 30 kg/m2). In total, 12.1% were current smokers, and 43.4% stated that they had
smoked in the past. Baseline characteristics according to dietary group (LPD versus HPD) are shown
in Table 1. Overall, the groups were similar upon entering the study, with no statistically significant
differences in anthropometric, lifestyle and basic clinical characteristics.
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Table 1. Baseline (week 0) participant characteristics according to the Polyphenol Intervention Trial
(PPhIT) study group allocation.
Low Polyphenol
(nmax = 50)
High Polyphenol
(nmax = 49)
Between-Group
Comparison p-Value *
Age (years) 55.6 ± 6.8 54.0 ± 7.0 0.25
Sex (males, n (%)) 30 (60.0) 23 (46.9) 0.23
Education (years) 13.9 (12.0, 16.8) 13.6 (13.8, 15.8) 0.57
Body mass index (kg/m2) 29.9 (26.9, 34.6) 31.15 (27.7, 33.5) 0.29
Waist circumference (cm)
Male 106.5 (98.0, 116.3) 105.0 (98.0, 116.0) 0.86
Female 94.0 (85.3, 108.8) 96.0 (89.5, 108.5) 0.56
Current smoker n (%) 5 (10.0) 7 (14.3) 0.55
Use of antidepressants n (%) 7 (14.0) 8 (16.3) 0.79
Systolic blood pressure (mmHg) 143.7 ± 6.6 143.6 ± 8.0 0.95
Diastolic blood pressure (mmHg) 86.9 ± 8.3 85.9 ± 7.1 0.55
Total cholesterol (mmol/L) 5.3 ± 1.2 5.7 ± 1.2 0.10
HDL(mmol/L) 1.4 ± 0.3 1.3 ± 0.4 0.58
LDL(mmol/L) 4.3 ± 1.3 4.6 ± 1.2 0.18
Triglycerides (mmol/L) 1.7 (1.6, 2.1) 1.6 (1.5, 2.0) 0.46
HDL—high-density lipoprotein; LDL—low-density lipoprotein. Continuous variables are summarised as mean
± SD or medians and interquartile ranges. Categorical variables are summarised as n (%). * Between-group
comparisons were made using independent sample t-tests (p < 0.05) or Mann–Whitney U test for continuous
variables and chi-squared tests (p < 0.05) for categorical variables.
During the washout period, no changes were recorded in participants’ physical activity habits,
weight status, smoking habits, medication use or clinical condition compared to baseline in both HPD
and LPD groups (data not shown). Additionally, mood evaluation according to PANAS questionnaire
did not record any change between baseline and end of washout period (both p > 0.05) (data not
shown). F&V intake per day declined significantly during washout, from 2.67 portions at week 0
to 1.38 portions at week 4 within the overall sample (p < 0.001), and significant reductions in blood
levels of vitamin C (p < 0.001) and β-cryptoxanthin (p = 0.05), but not in any of the other carotenoids
measured, were also recorded (data not shown).
Dietary intake of food groups and micronutrients, as well as weight status and physical activity
levels both at baseline and at the end of the intervention period, are presented in Table 2, per intervention
group. At baseline, there was no significant difference in intake of F&V, berries and dark chocolate and
concentration of micronutrients between the LPD and HPD group. By the end of the intervention,
there was a significant increase in intake of F&V, berries and dark chocolate in the HPD group, and the
differences in change in intake between the two groups were statistically significant. Furthermore,
there was a significant increase in the concentration of biomarkers, plasma vitamin C, serum lutein,
β-cryptoxanthin, α-carotene and lycopene and urinary epicatechin over the course of the intervention
in the HPD group, and the differences in the change in the concentration between the LPD and HPD
group were statistically significant. These results indicate good compliance with the intervention diet,
with significant between-group differences in change in all biomarkers measured except β-carotene.
No differences were recorded in change in physical activity and weight status between the two
intervention groups during the intervention.
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Table 2. Baseline (week 0) and end of intervention (week 12) dietary intake, plasma, serum and urine micronutrient biomarkers, physical activity and weight status
characteristics according to the Polyphenol Intervention Trial (PPhIT) study group allocation.
Low Polyphenol Diet (nmax = 50) High Polyphenol Diet (nmax = 49)
Week 0 1 Week 12
Median Change
(IQR) 3
Within Group
(p Value) 4 Week 0
1 Week 12 Median Change(IQR) 3
Within Group
(p Value) 4
Between Group
(p Value) 5
Dietary intake
Fruits and vegetables
intake (portions/day) 2.68 ± 1.68) 1.24 ± 0.56 −1.44 (−1.87, −0.95) <0.001 2.64 ± 1.70 6.73 ± 2.07 4.09 (3.45, 4.73) <0.001 <0.001
Week 0 1 Week 12
Median Change
(IQR) 3
Within Group
(p value) 4 Week 0
1 Week 12 Median Change(IQR) 3
Within Group
(p value) 4
Between Group
(p value) 5
Berries (portions/day) 0 (0.00, 0.00) 0 (0.00, 0.00) 0 (0.00, 0.00) 0.69 0 (0.00, 0.00) 1 (0.80, 1.25) 1 (0.75, 1.17) <0.001 <0.001
Dark chocolate
(grams/day) 0 (0.00, 0.00) 0 (0.00, 0.00) 0 (0.00, 0.00) 0.18 0 (0.00, 0.00) 50 (37.50, 50.00) 50 (37.5, 50.0) <0.001 <0.001
Micronutrient
biomarkers
Vitamin C (µmol/l) 6 44.3 (28.70, 61.90) 34.2 (13.40, 49.50) −7.60 (−26.50, 0.85) <0.001 46.4 (31.70, 65.00) 55.7 (43.10, 68.20) 4.83 (−8.68, 20.75) 0.1 <0.001
Total carotenoids
(µmol/l) 6 1.09 (0.88, 1.43) 1.09 (0.72, 1.35) −0.01 (−0.03, 0.01) 0.01 1.17 (0.96, 1.48) 1.33 (1.06, 1.66) 0.12 (−0.12, 0.40) 0.07 <0.001
Lutein (µmol/l) 6 0.15 (0.12, 0.22) 0.14 (0.11, 0.20) −0.01 (−0.03, 0.01) 0.08 0.14 (0.11, 0.20) 0.20 (0.15, 0.26) 0.04 (0.01, 0.07) <0.001 <0.001
Zeaxanthin (µmol/l) 6 0.04 (0.03, 0.05) 0.03 (0.03, 0.05) −0.00 (−0.01, 0.01) 0.3 0.04 (0.03, 0.05) 0.04 (0.04, 0.06) 0 (−0.00, 0.01) 0.01 0.01
β-cryptoxanthin
(µmol/l) 6 0.06 (0.04, 0.07) 0.05 (0.03, 0.08) −0.01 (−0.02, 0.01) 0.049 0.06 (0.04, 0.09) 0.07 (0.05, 0.09) 0.01 (−0.01, 0.03) 0.03 <0.001
α-carotene (µmol/l) 6 0.12 (0.09, 0.15) 0.1 (0.08, 0.15) −0.01 (−0.04, 0.01) 0.06 0.13 (0.11, 0.18) 0.15 (0.11, 0.20) 0.01 (−0.02, 0.03) 0.17 0.02
β-carotene (µmol/l) 6 0.23 (0.16, 0.34) 0.22 (0.13, 0.32) −0.01 (−0.09, 0.03) 0.07 0.27 (0.19, 0.44) 0.3 (0.21, 0.41) −0.00 (−0.06, 0.08) 0.79 0.14
Lycopene (µmol/l) 6 0.49 (0.38, 0.66) 0.47 (0.33, 0.58) −0.04 (−0.19, 0.09) 0.07 0.5 (0.39, 0.61) 0.56 (0.40, 0.68) 0.05 (−0.14, 0.21) 0.31 0.048
Epicatechin
(nmol/mg crt/L) 6 0.43 (0.17, 1.10) 0.55 (0.26, 1.00) 0.04 (−0.24, 0.32) 0.37 0.64 (0.25, 0.97) 1.73 (0.51, 4.20) 0.89 (0.10, 3.57) <0.001 <0.001
Week 0 1 Week 12
Mean Change (95%
CI) 2
Within Group (p
value) 4 Week 0
1 Week 12 Mean Change(95% CI) 2
Within Group (p
value) 4
Between Group
(p value) 5
Physical activity
(MET hours/day)
Sedentary activities 8.9 ± 4.7 8.6 ± 4.6 −0.3 (−1.0, 0.4) 0.6 8.4 ± 4.7 8.2 ± 4.8 −0.2 (−1.0, 0.7) 0.72 0.77
Moderate intensity 3.7 ± 5.6 2.6 ± 4.7 −1.1 (−2.3, 0.2) 0.1 3.9 ± 5.4 3.0 ± 5.4 −0.9 (−2.0, 0.2) 0.049 0.78
Vigorous intensity 1.1 ± 4.5 0.2 ± 0.5 −1.0 (−2.2, 0.3) 0.33 0.3 ± 1.6 0.1 ± 0.5 −0.2 (−0.6, 0.3) 0.89 0.63
Weight (kg) 87.2 ± 19.1 87.0 ± 19.1 −0.15 (−0.7, 0.4) 0.56 88.0 ± 20.1 88.2 ± 20.4 0.20 (−0.22, 6.2) 0.35 0.29
MET – metabolic equivalent of task. Data are presented as mean ± SD or medians and interquartile ranges (IQR). 1 There were no significant between-group differences in baseline values;
2 mean change was calculated as week 12- week 0 and is presented as mean change (95% CI); 3 median change was calculated as week 12- week 0 and is presented as median change (IQR);
4 within-group comparisons were performed using paired sample t tests and Wilcoxon signed-rank test (p < 0.05); 5 between-group comparisons were made using independent sample
t-tests and Mann–Whitney U test (p < 0.05); 6 all variables are logarithmically transformed and summarised as geometric medians (IQ range) and change as geometric median change (IQR).
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3.2. Changes in Aspects of Psychological Well-Being
Changes in measures of psychological well-being between baseline and intervention are illustrated
in Table 3. There were no significant differences in scores of BDI-II, DASS-21 or PANAS between the
LPD and HPD groups at baseline. There was a significant between-group difference (p = 0.01) in
change in depressive symptoms as assessed with BDI-II, but no other significant effects were found
between groups with regards to depression, anxiety or stress measured using the DASS-21 or positive
and negative affect measured with PANAS. Regarding within-group changes, a borderline significant
(p = 0.05) result was detected for a reduction in stress measured by DASS-21 within the HPD group,
as well as an improvement in subjective mood (positive affect) (p = 0.03) measured by PANAS.
3.3. Changes in Self-Esteem and Body Image Perception
There were no significant differences in self-esteem or body image perception scores between
the LPD and HPD groups at baseline. As shown in Table 3, there were also no significant differences
between the HPD and LPD in self-esteem or body image perception scores at the end of the intervention.
3.4. Changes in Health-Related Quality of Life
There were no significant differences between groups at baseline with regards to health-related
quality of life measured using the SF-36. There were statistically significant between-group differences
in change in different component scores (general health (p = 0.03) and energy/fatigue (p = 0.02)) and
the overall summary scores for the physical health component (p = 0.04) and mental health component
(p = 0.01), with more positive changes demonstrated in the HPD group. In the HPD group, there
were also within-group improvements in role limitations due to physical health (p = 0.04), general
health (p = 0.00), energy/fatigue (p = < 0.001), emotional well-being (p = < 0.001) and social functioning
(p = 0.02)
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Table 3. Changes in mood, self-esteem, body image and quality of life indicators according to the Polyphenol Intervention Trial (PPhIT) study group allocation.
Low Polyphenol Diet (nmax = 50) High Polyphenol Diet (nmax = 49)
Week 0 1 Week 12
Median Change
(IQR) 2
Within Group
Change (p Value) 3 Week 0
1 Week 12 Median Change(IQR) 2
Within Group
Change (p Value) 3
Between Group
Change (p Value) 4
BDI-II * 6.0 (2.0, 12.5) 7.0 (2.0, 11.0) 0.2 (−1.5, 1.9) 0.98 6.0 (3.0, 12.0) 2.0 (0.0, 6.0) −3.4 (−5.4, −1.5) <0.001 0.01
DASS-21 **
Depression 5 2.0 (0.0, 12.0) 6.0 (0.0, 10.5) 0 (−2.0, 6.0) 0.29 2.0 (0.0, 10.0) 0.0 (0.0, 6.0) 0 (−2.0, 0.0) 0.53 0.56
Anxiety 5 4.0 (2.0, 9.0) 2.0 (0.0, 8.0) 0.0 (−3.0, 3.0) 0.86 4.0 (0.0, 10.0) 2.0 (0.0, 6.0) 0.0 (−2.0, 0.0) 0.16 0.8
Stress 5 7.0 (2.0, 12.5) 8.0 (0.0, 16.0) 0 (−2.0, 4.0) 0.76 6.0 (2.0, 14.0) 4.0 (0.0, 10.0) −2.0 (−6.0, 2.0) 0.05 0.14
PANAS ***
Positive affect 29.9 (8.3) 30.4 (9.8) 0.5 (−1.5, 2.5) 0.63 33.0 (6.8) 35.2 (7.4) 2.2 (0.3, 4.1) 0.03 0.21
Negative affect 11.0 (10.0, 13.0) 11.0 (10.0, 13.0) 0.0 (−1.5, 1.5) 0.56 12.0 (10.0, 15.0) 10.0 (10.0, 14.0) 0.0 (−1.0, 0.5) 0.68 0.99
Rosenberg Self-Esteem Score † 26.0 (25.0, 28.0) 26.0 (25.0, 28.0) 0.0 (−2.0, 2.0) 0.74 26.0 (25.0, 27.0) 27.0 (24.0, 27.0) 0.0 (−2.0, 2.0) 0.68 0.53
MBSRQ-AS ††
Appearance Evaluation 2.9 (2.4, 3.5) 3.0 (2.4, 3.6) 0.0 (−0.3, 0.4) 0.27 3.0 (2.5, 3.4) 3.1 (2.7, 3.6) 0.1 (−0.3, 0.4) 0.15 0.76
Appearance Orientation 3.0 (2.5, 3.7) 3.0 (2.5, 3.7) 0.0 (−0.3, 0.2) 0.35 3.2 (2.8, 3.5) 3.3 (2.9, 3.8) 0.2 (−0.2, 0.4) 0.16 0.1
Body areas Satisfaction 3.0 (2.7, 3.4) 3.3 (2.4, 3.7) 0.2 (−0.1, 0.4) 0.03 3.1 (2.7, 3.6) 3.3 (2.8, 3.8) 0.2 (−0.1, 0.3) 0.02 0.71
Overweight Preoccupation 2.3 (1.8, 2.8) 2.4 (1.8, 2.8) 0.0 (−0.3, 0.5) 0.87 2.5 (1.8, 3.3) 2.6 (1.8, 3.2) 0.0 (−0.5, 0.3) 0.45 0.72
Self-classified Weight 1 4.0 (3.4, 4.0) 4.0 (3.0, 4.0) 0.0 (0.0, 0.0) 0.08 4.0 (3.5, 4.0) 4.0 (3.5, 4.0) 0.0 (0.0, 0.0) 0.43 0.5
SF-36 †††
Physical Functioning 90 (75.0, 97.5) 90 (81.3, 100.0) 0 (0.0, 10.0) 0.07 95 (80.0, 100.0) 95 (85.0, 100.0) 0 (−5.0, 10.0) 0.15 0.44
Role limitations—physical health 100 (37.5, 100.0) 100 (37.5, 100.0) 0 (0.0, 25.0) 0.45 100 (75.0, 100.0) 100 (100.0, 100.0) 0 (0.0, 0.0) <0.001 0.61
Pain 80 (47.5, 100.0) 80 (46.3, 100.0) 0 (−10.0, 10.0) 0.64 90 (60.0, 90.0) 90 (70.0, 100.0) 0 (−10.0, 22.5) 0.2 0.51
General health 65 (45.0, 75.0) 60 (50.0, 75.0) 0 (−10.0, 10.0) 0.47 65 (50.0, 75.0) 75 (65.0, 85.0) 10 (−5.0, 20.0) <0.001 0.03
Physical health component 210.5 (168.5, 223.1) 200.9 (172.9, 217.2) −6.4 (−17.0, 4.2) 0.09 213.2 (189.6, 225.1) 216.6 (201.4, 225.3) 2.2 (−8.1, 15.4) 0.2 0.04
Role limitations—emotional health 100 (100.0, 100.0) 100 (100.0, 100.0) 0 (0.0, 0.0) 0.99 100 (100.0, 100.0) 100 (100.0, 100.0) 0 (0.0, 0.0) 0.1 0.85
Energy/fatigue 55 (40.0, 72.5) 60 (45.0, 70.0) 5 (−5.0, 10.0) 0.39 60 (50.0, 80.0) 70 (60.0, 80.0) 5 (0.0, 20.0) <0.001 0.02
Emotional well-being 76 (64.0, 84.0) 80 (62.0, 86.0) 0 (−8.0, 8.0) 0.73 80 (60.0, 88.0) 84 (72.0, 92.0) 4 (0.0, 16.0) 0 0.01
Social functioning 100 (75.0, 100.0) 100 (75.0, 100.0) 0 (−6.3, 0.0) 0.97 100 (75.0, 100.0) 100 (100.0, 100.0) 0 (0.0, 25.0) 0.02 0.08
Mental health component 209.1 (176.8, 222.3) 197.9 (175.0, 217.2) −4.0 (−26.6, 8.1) 0.04 208 (181.4, 226.0) 218.3 (201.4, 226.8) 1.9 (−6.9, 19.1) 0.09 0.01
Data are presented as mean ± SD or medians and interquartile ranges (IQR). 1 There were no significant between-group differences in baseline values; 2 median change was calculated as
week 12- week 0 and is presented as median change (IQR); 3 within-group comparisons were performed using paired sample t test or Wilcoxon signed-rank test (p < 0.05); 4 between-group
comparisons were made using Mann–Whitney U test for continuous variables (p < 0.05); 5 n = 57 (LPD (n = 27), HPD (n = 30)); * BDI-II; Beck Depression Inventory Second Edition. Scores
0–13 = minimal depression, 14–19 = mild depression, 20–28 = moderate depression, 29–63 = severe depression; ** DASS-21; Depression Anxiety and Stress Scale 21 items. Depression score
0–9 = normal, Anxiety score 0–7 = normal, Stress score 0–14 = normal; *** PANAS; Positive and Negative Affect Scale. Higher score indicates higher positive and negative affect; † Rosenberg
Self-Esteem Score; scores range from 0 to 30. Higher scores are indicative of higher self-esteem; †† MBSRQ-AS; Multi-Dimensional Body-Self Relations Questionnaire—Appearance Scales.
Higher scores indicative of higher body image satisfaction; ††† Mental and physical health assessed using the RAND 36-Item Short Form Survey (SF-36). Physical functioning scores: “low”
= limited a lot in performing all physical activities including bathing or dressing, “high” = performs all types of physical activities including the most vigorous without limitations due to
health; Role limitations due to physical problems: “low” = problems with work or other daily activities as a result of physical health, “high” = no problems with work or other daily
activities as result of physical health, past 4 weeks; Pain: “high” = very severe and extremely limiting pain, “low” = no pain or limitations due to pain, past 4 weeks; General health
perceptions: “high” = believes personal health is poor and likely to get worse, “low” = believes personal health is excellent. Physical health component = sum of physical functioning, role
limitations—physical health, pain and general health. Role limitations due to emotional problems: “high” = problems with work or other daily activities as a result of emotional problems,
“low” = no problems with work or other daily activities as result of emotional problems, past 4 weeks; Energy/fatigue: “low” = feels tired and worn out all of the time, “low” = feels full of
pep and energy all of the time, past 4 weeks; Emotional well-being: “high” = feelings of nervousness and depression all of the time, “low” = feels peaceful, happy and calm all of the time,
past 4 weeks; Social functioning: “low” = extreme and frequent interference with normal social activities due to physical and emotional problems, “high” = performs normal social
activities without interference due to physical or emotional problems, past 4 weeks. Mental health component = sum of role limitations—emotional health, energy/fatigue, emotional
well-being and social functioning.
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4. Discussion
Given the high prevalence of mental health problems and the potential effect of dietary
patterns on their onset and/or treatment, the aim of the present study was to assess the effect of
a polyphenol-rich dietary pattern (comprising fruits, including berries; vegetables and dark chocolate)
on aspects of psychological well-being or mental health status, including mood, self-esteem and
body image perception, as secondary outcomes of the PPhIT study. Despite some heterogeneity,
the study findings suggest that the adoption of such a polyphenol-rich diet could potentially lead to
beneficial effects on certain outcomes including depressed mood and physical and mental health in
hypertensive participants.
There was a significant difference in change in depressive symptoms assessed with BDI-II between
the HPD group and the LPD group, indicating a positive effect of the HPD, which is in agreement with
a number of other observational studies focusing on the same outcome measure and polyphenol-rich
foods. In the HPD group, a 66.6% reduction in BDI-II score was observed after the intervention.
Button et al. 2015, using data from three randomised controlled trials (RCT) with a sample of n = 1039,
identified that a 17.5% reduction in score was necessary to observe minimally clinically important
differences [46]. Oliveria et al. (2019) found a negative association between depressive symptoms
measured by BDI and high intake of polyphenol food items [47]. In the Finnish general population
(n = 2011), daily intake of tea was associated with reduced risk of depressive symptoms defined by
BDI scores [48]. Similarly, in the Mediterranean healthy eating, lifestyle and aging (MEAL) study
(n = 1572), the dietary intake of phenolic acid, flavanones and anthocyanin were negatively associated
with depressive symptoms measured using the Center for Epidemiologic Studies Depression Scale
(CES-D-10) [49]. The positive effects observed in the present study may be attributable to other
nutrients found in F&V, berries and dark chocolate which may work independently or synergistically
to influence health outcomes. Brody (2002) found that vitamin C intake over a 14 day period led to a
moderate reduction in depressive symptoms amongst 42 healthy young adults [50]. In our study, there
was a significant difference in plasma vitamin C status between the LPD and HPD group. Similarly,
there were significant increases in serum carotenoids, lutein, zeaxanthin, β-cryptoxanthin and urinary
epicatechin within the HPD group, and some studies have suggested a link between these nutrients
and improvements in psychological well-being including depression [51]. The antidepressant effects of
polyphenols may be associated with both their antioxidant and anti-inflammatory properties, whereby
there is a reduction in free radicals and cytokine dysregulation [12]. Lua and Wong (2012) found that
the consumption of 50 g dark chocolate (70% cocoa) for three days was associated with significant
improvement in depressed mood [52].
The primary outcome of the PPhIT study was to identify whether high consumption of F&V, berries
and dark chocolate could improve microvascular function in hypertensive subjects [30]. High intake
of polyphenol, specifically including F&V, berries and dark chocolate in diet, resulted in significant
improvements in endothelium-dependent (acetylcholine) vasodilator [30]. Depression is often observed
among individuals with vascular diseases such as hypertension, peripheral vascular disease and
coronary artery disease, known as “vascular depression hypothesis” [53]. Studies have reported
morphological changes in vascular structure and altered expression of endothelial cell molecules
such as nitric oxide in patients with depression [53]. In the current study, the improvements in
endothelium-dependent vasodilatation might have also resulted in improvements in depressed mood.
In light of the findings from the BDI-II, it is interesting that no notable effects of the polyphenol-rich
diet were observed on depressed mood measured using the DASS-21 questionnaire in this study.
The DASS-21 questionnaire was introduced as an amendment to PPhIT, given concerns that BDI-II
is used to screen for depression in normal populations or to assess severity of depression in clinical
populations, and therefore it was thought possible by the research team that the tool may not have
been sensitive enough to pick up changes due to diet. Page et al. (2007) showed that DASS-21
has good psychometric properties and is moderately sensitive to changes that result from the
treatment [54]. However, this resulted in a considerably smaller sample size for the analysis of the
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DASS-21 questionnaire (n = 57) compared to BDI-II, which may have had implications in terms of the
associated power available to detect differences between the two diet groups. The DASS-21 also showed
no statistically significant differences in change between groups with regards to stress or anxiety.
Furthermore, for both measures, scores on all scales at the start of the study are low, and negative affect
scores for the PANAS are also low. These low scores are unsurprising in a volunteer sample for a study
intended to improve health but may also have limited our chances of finding effects. Further study in
groups with higher levels of poor psychological health, e.g., those with diagnoses of depression or
anxiety, may be of value.
In the present study, significant improvements in quality of life between the HPD group and the
LPD group measured using the SF-36 health survey questionnaire were found. There were statistically
significant improvements in both physical and mental health components in the HPD group when
compared with the LPD group. Data showing the effect of dietary interventions and especially of
polyphenols/antioxidants on quality of life parameters are sparse and mainly limited to patients with
chronic diseases such as multiple sclerosis, chronic fatigue syndrome and depression. Steptoe et al.
(2004) found that a higher intake of fruits and vegetables through behavioural and nutrition education
counselling was positively associated with physical health status but not mental health status measured
using SF-36 among adults in a low-income neighbourhood [55]. A sub-study of the DASH trial also
found that adhering to a fruit and vegetable-rich diet was associated with improved perception of
quality of life [56]. It is important to acknowledge that while the self-reported improvements in physical
and mental health scores observed within the current sample may be attributed to the foods consumed,
they may also be wholly or partly influenced by taking part in the intervention and increased positivity
that may come from making positive dietary changes. As pointed out in the study by Plaisted et al.
(1999), improvements in QoL might be attributable to participants’ awareness that they are consuming
a healthy diet, which could have contributed to improved self-ratings of general health and mental
health component [56]. In addition, given that depressive symptoms were improved in the HPD group,
the improvements in mental health component may simply mirror these findings.
It is important to consider the results of this study in light of a number of methodological
limitations. Firstly, as the primary purpose of PPhIT was to test the effect of a polyphenol-rich dietary
pattern on microvascular and platelet function, the outcomes discussed here are secondary endpoints.
Hence, as mentioned previously, it is possible that the study may not have been adequately powered
to detect differences between the dietary groups, which may account for some of the null findings
demonstrated. Secondly, the study sample comprised mildly hypertensive participants, which limits
the generalisability of these results to the wider population. Furthermore, it is possible that selection
bias exists within the current sample, given that the volunteers for this study were on the whole
well-educated, and, as is the case with most clinical trials, are likely to have been more motivated with
regard to improving their health than the general population. The participants in the HPD group were
provided with the key intervention foods on a weekly basis, whereas the LPD group received no food
provision as their diet was to remain unchanged. This may have increased the likely compliance of the
HPD group with the intervention. Another limitation of this study was the use of self-report measures
to measure psychological outcomes. Self-report measures can be disadvantageous in that they can
be affected by forms of bias, including response, recall and social desirability bias, which can lead
to inaccurate responses and conclusions [57]. However, given the subjective nature of psychological
well-being, self-reporting is the most suitable method of obtaining information on individuals’ personal
experiences and emotions. The current study employed validated and previously used measures to
collect information on individuals’ personal experiences and emotions [58,59]. Additionally, it must be
noted that the questionnaires described in this study were distributed at week 0 (baseline) and week
12 (intervention). It is possible that the washout period (week 0 to week 4) could have potentially
affected people’s psychological well-being and thus it may have been useful to additionally measure the
endpoints at week 4. However, the decision to distribute the questionnaires at week 0 and week 12 was
made for three main reasons: (i) to reduce participant burden at week 4 visits, which were already long
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(2.5 h) in duration due to vascular function assessment and the dissemination of dietary advice; (ii) the
study wished to investigate the effect of the intervention diet in comparison to normal psychological
status, rather than psychological states under controlled conditions, which would have limited the
applicability of the results; (iii) distributing the outcome measures at three time points may have
been disadvantageous in terms of allowing participants to become familiar with their format, which
may have induced response bias. Another limitation common to most studies analysing self-reported
questionnaire data is the number of variables assessed, which may have increased the chance of type
one errors (identification of the false positive) associated with hypothesis testing.
In contrast, one of the most obvious strengths of this study is its RCT study design. However,
as the randomisation according to the groups only occurred at week 4, the presentation of week 0 data
based on the allocated groups is rather artificial, and this must be considered a limitation. As further
strengths, the study implemented a variety of techniques to encourage and monitor compliance.
As a result of such efforts, participants were demonstrated to have good compliance with both diets,
which was assessed both subjectively and objectively. Furthermore, the study had good retention of
participants, with a less than 5% (n = 5) drop out level, all of which were due to reasons unrelated to
the study.
5. Conclusions
In conclusion, the results from the present RCT trial showed heterogeneous findings regarding the
effect of a polyphenol-rich dietary pattern on aspects of psychological well-being, with positive effects
demonstrated on depressive symptoms and both the physical and mental health status components of
the SF-36 quality of life measure. Further studies with psychological well-being impacts as primary
endpoints, with appropriate study design and sample sizes, are needed in order to confirm the benefits
of a polyphenol-rich dietary pattern on these outcomes.
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